UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 531

Sortiert nach

Pantoea septica bacteremia in a 3-month-old infant with RAG2 severe combined immune deficiency: A case report

Diagnostic microbiology and infectious disease, 2024-11, Vol.110 (3), p.116499, Article 116499

2024

Volltextzugriff (PDF)

Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

Drugs (New York, N.Y.), 2024-08

2024

Volltextzugriff (PDF)

Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21

Journal of antimicrobial chemotherapy, 2024-08

2024

Volltextzugriff (PDF)

How is ceftobiprole used in Canada: the CLEAR study final results

Expert review of anti-infective therapy, 2024-07, p.1-8

2024

Volltextzugriff (PDF)

Invasive pneumococcal disease surveillance in Canada, 2021–2022

Canada communicable disease report, 2024-05, Vol.50 (5), p.121-134

2024

Volltextzugriff (PDF)

Global transmission of extended-spectrum cephalosporin resistance in Escherichia coli driven by epidemic plasmidsResearch in context

EBioMedicine, 2024-05, Vol.103, p.105097

2024

Volltextzugriff (PDF)

Global transmission of extended-spectrum cephalosporin resistance in Escherichia coli driven by epidemic plasmids

EBioMedicine, 2024-05, Vol.103, p.105097-105097, Article 105097

2024

Volltextzugriff (PDF)

Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021)

Diagnostic microbiology and infectious disease, 2024-02, Vol.108 (2), p.116130-116130, Article 116130

2024

Volltextzugriff (PDF)

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials

Expert review of anti-infective therapy, 2023-11, Vol.21 (11), p.1213-1225

2023

Volltextzugriff (PDF)

The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis

Expert review of neurotherapeutics, 2023-10, Vol.23 (10), p.921-930

2023

Volltextzugriff (PDF)

Part 1: Mucormycosis: prevalence, risk factors, clinical features, and diagnosis

Expert review of anti-infective therapy, 2023-07, Vol.21 (7), p.723-736

2023

Volltextzugriff (PDF)

Part 2: mucormycosis: focus on therapy

Expert review of anti-infective therapy, 2023-07, Vol.21 (7), p.737-748

2023

Volltextzugriff (PDF)

Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i2-i7

2023

Volltextzugriff (PDF)

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i8-i16

2023

Volltextzugriff (PDF)

Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i17-i25

2023

Volltextzugriff (PDF)

S treptococcus pneumoniae serotyping and antimicrobial susceptibility: a ssessment for v accine e fficacy in Canada after the introduction of PCV13

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i2-i7

2023

Volltextzugriff (PDF)

Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011–20

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i37-i47

2023

Volltextzugriff (PDF)

Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011–2020

Journal of antimicrobial chemotherapy, 2023-05, Vol.78 (Supplement_1), p.i26-i36

2023

Volltextzugriff (PDF)

Escalation of antimicrobial resistance among MRSA part 1: focus on global spread

Expert review of anti-infective therapy, 2023-02, Vol.21 (2), p.99-113

2023

Volltextzugriff (PDF)

Escalation of antimicrobial resistance among MRSA part 2: focus on infections and treatment

Expert review of anti-infective therapy, 2023-02, Vol.21 (2), p.115-126

2023

Volltextzugriff (PDF)

Dynamics of extended-spectrum cephalosporin resistance genes in Escherichia coli from Europe and North America

Nature communications, 2022-12, Vol.13 (1), p.7490-7490, Article 7490

2022

Volltextzugriff (PDF)

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020

JAC-antimicrobial resistance, 2022-12, Vol.4 (6), p.dlac122-dlac122

2022

Volltextzugriff (PDF)

In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014–21)

Journal of antimicrobial chemotherapy, 2022-11, Vol.77 (12), p.3414-3420

2022

Volltextzugriff (PDF)

In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study

Journal of antimicrobial chemotherapy, 2022-10, Vol.77 (11), p.3035-3038

2022

Volltextzugriff (PDF)

A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017

Antimicrobial agents and chemotherapy, 2022-10, Vol.66 (10), p.e0067722

2022

Volltextzugriff (PDF)

1 – 25 von 531

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(519)
Mit Volltextzugriff
(481)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(380)
Life Sciences & Biomedicine
(372)
Microbiology
(284)
Humans
(275)
Pharmacology & Pharmacy
(250)
Infectious Diseases
(205)
Microbial Sensitivity Tests
(198)
Anti-Bacterial Agents - Pharmacology
(182)
Biological And Medical Sciences
(178)
Medical Sciences
(170)
Pharmacology. Drug Treatments
(146)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(145)
Streptococcus Pneumoniae
(85)
Antibacterial Agents
(79)
Streptococcus Pneumoniae - Drug Effects
(66)
Drug Resistance, Bacterial
(65)
Canada
(62)
Escherichia Coli
(62)
Pseudomonas Aeruginosa
(61)
Anti-Bacterial Agents - Therapeutic Use
(57)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Pantoea septica bacteremia in a 3-month-old infant with RAG2 severe combined immune deficiency: A case report

Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21

How is ceftobiprole used in Canada: the CLEAR study final results

Invasive pneumococcal disease surveillance in Canada, 2021–2022

Global transmission of extended-spectrum cephalosporin resistance in Escherichia coli driven by epidemic plasmidsResearch in context

Global transmission of extended-spectrum cephalosporin resistance in Escherichia coli driven by epidemic plasmids

Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021)

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in Canada: treatment update and the role of new IV antimicrobials

The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis

Part 1: Mucormycosis: prevalence, risk factors, clinical features, and diagnosis

Part 2: mucormycosis: focus on therapy

Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV13

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020

Analysis of MDR in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–2020

S treptococcus pneumoniae serotyping and antimicrobial susceptibility: a ssessment for v accine e fficacy in Canada after the introduction of PCV13

Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011–20

Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011–2020

Escalation of antimicrobial resistance among MRSA part 1: focus on global spread

Escalation of antimicrobial resistance among MRSA part 2: focus on infections and treatment

Dynamics of extended-spectrum cephalosporin resistance genes in Escherichia coli from Europe and North America

Antimicrobial resistance patterns of bacterial pathogens recovered from the urine of patients at Canadian hospitals from 2009 to 2020

In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014–21)

In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study

A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017

Suchergebnisse filtern